Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group.

N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.

PMID:
30575490
2.

Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.

Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M, Erkan M, Kleeff J, Wilson J, Apte M, Tosolini M, Wilson AS, Delvecchio FR, Bousquet C, Paradis V, Hammel P, Sadanandam A, Kocher HM.

J Pathol. 2018 Dec 21. doi: 10.1002/path.5224. [Epub ahead of print]

PMID:
30575030
3.

Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005.

Wisniewski M, Placide PA, Granier S, Al Shatti Y, Al Qalaf S, Bouattour M, Lamuraglia M, Hammel P.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):399-402. doi: 10.21037/hbsn.2018.08.03. No abstract available.

4.

Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor.

Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R.

J Visc Surg. 2018 Dec;155(6):483-492. doi: 10.1016/j.jviscsurg.2018.08.010. Epub 2018 Nov 15.

PMID:
30448206
5.

Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer.

Sheel ARG, Harrison S, Sarantitis I, Nicholson JA, Hanna T, Grocock C, Raraty M, Ramesh J, Farooq A, Costello E, Jackson R, Chapman M, Smith A, Carter R, Mckay C, Hamady Z, Aithal GP, Mountford R, Ghaneh P, Hammel P, Lerch MM, Halloran C, Pereira SP, Greenhalf W.

Am J Gastroenterol. 2019 Jan;114(1):155-164. doi: 10.1038/s41395-018-0395-y.

PMID:
30353057
6.

Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018.

Vangala DB, Cauchin E, Balmaña J, Wyrwicz L, van Cutsem E, Güller U, Castells A, Carneiro F, Hammel P, Ducreux M, van Laethem JL, Matysiak-Budnik T, Schmiegel W.

Eur J Cancer. 2018 Nov;104:91-103. doi: 10.1016/j.ejca.2018.09.004. Epub 2018 Oct 18.

PMID:
30342310
7.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.

Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O.

Gastric Cancer. 2018 Oct 11. doi: 10.1007/s10120-018-0885-z. [Epub ahead of print]

PMID:
30311042
8.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD); Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d’Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO); Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT); Association Française de Chirurgie (AFC).

Dig Liver Dis. 2018 Dec;50(12):1257-1271. doi: 10.1016/j.dld.2018.08.008. Epub 2018 Aug 18. Review.

PMID:
30219670
9.

Voltage-driven, local, and efficient excitation of nitrogen-vacancy centers in diamond.

Labanowski D, Bhallamudi VP, Guo Q, Purser CM, McCullian BA, Hammel PC, Salahuddin S.

Sci Adv. 2018 Sep 7;4(9):eaat6574. doi: 10.1126/sciadv.aat6574. eCollection 2018 Sep.

10.

[Role of radiation therapy in the management of pancreatic cancer].

Huguet F, Rivin Del Campo E, Antoni D, Vendrely V, Hammel P.

Cancer Radiother. 2018 Oct;22(6-7):552-557. doi: 10.1016/j.canrad.2018.06.005. Epub 2018 Aug 9. Review. French.

PMID:
30100126
11.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D.

Eur J Hum Genet. 2018 Dec;26(12):1732-1742. doi: 10.1038/s41431-018-0224-1. Epub 2018 Aug 8.

PMID:
30089825
12.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.

Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10.

PMID:
29991024
13.

Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process.

Faille D, Bourrienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, Panicot-Dubois L, Hammel P, Lévy P, Ruszniewski P, Ajzenberg N, Rebours V.

Oncotarget. 2018 May 29;9(41):26453-26465. doi: 10.18632/oncotarget.25458. eCollection 2018 May 29.

14.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P.

Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.

PMID:
29756206
15.

Preoperative imaging and pathologic classification for pancreatic neuroendocrine tumors.

Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R.

J Visc Surg. 2018 Apr;155(2):117-125. doi: 10.1016/j.jviscsurg.2017.12.008. Epub 2018 Feb 12. Review.

PMID:
29397338
16.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
17.

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527. Epub 2017 Aug 12. Review.

18.

Metallic ferromagnetic films with magnetic damping under 1.4 × 10-3.

Lee AJ, Brangham JT, Cheng Y, White SP, Ruane WT, Esser BD, McComb DW, Hammel PC, Yang F.

Nat Commun. 2017 Aug 10;8(1):234. doi: 10.1038/s41467-017-00332-x.

19.

5-Fluorouracil biomarkers in pancreatic neuroendocrine tumours.

de Mestier L, Cros J, Hammel P.

Pancreatology. 2017 Jul - Aug;17(4):527-528. doi: 10.1016/j.pan.2017.06.004. Epub 2017 Jun 8. No abstract available.

PMID:
28619285
20.

Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.

Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P.

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):904-908. doi: 10.1097/MEG.0000000000000901.

PMID:
28471829
21.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.

PMID:
28397697
22.

Surgery for pancreatic neoplasms: How accurate are our surgical indications?

Birnbaum DJ, Gaujoux S, Berbis J, Dokmak S, Hammel P, Vullierme MP, Lévy P, Sauvanet A.

Surgery. 2017 Jul;162(1):112-119. doi: 10.1016/j.surg.2017.01.015. Epub 2017 Feb 23.

PMID:
28237644
23.

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer.

Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.

24.

Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey.

Hammel P, Coriat R, Lledo G, de Bausset M, Selosse M, Obled S, Bonnetain F.

Bull Cancer. 2017 Apr;104(4):321-331. doi: 10.1016/j.bulcan.2016.11.022. Epub 2017 Jan 11.

PMID:
28087054
25.

Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.

Oudard S, Elaidi R, Brizard M, Le Rest C, Caillet V, Deveaux S, Benoit G, Corréas JM, Benoudiba F, David P, Gaudric A, Hammel P, Joly D, Timsit MO, Méjean A, Richard S.

Oncotarget. 2016 Dec 20;7(51):85306-85317. doi: 10.18632/oncotarget.13301.

26.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885
27.

[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].

Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T.

Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6. French.

PMID:
27507031
28.

Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply.

Huguet F, Goldstein D, Hammel P.

JAMA. 2016 Oct 4;316(13):1409-1410. doi: 10.1001/jama.2016.9781. No abstract available.

PMID:
27701655
29.

Biodegradable and plasma-treated electrospun scaffolds coated with recombinant Olfactomedin-like 3 for accelerating wound healing and tissue regeneration.

Dunn LL, de Valence S, Tille JC, Hammel P, Walpoth BH, Stocker R, Imhof BA, Miljkovic-Licina M.

Wound Repair Regen. 2016 Nov;24(6):1030-1035. doi: 10.1111/wrr.12485. Epub 2016 Oct 12.

PMID:
27684720
30.

Magnetic resonance force detection using a membrane resonator.

Scozzaro N, Ruchotzke W, Belding A, Cardellino J, Blomberg EC, McCullian BA, Bhallamudi VP, Pelekhov DV, Hammel PC.

J Magn Reson. 2016 Oct;271:15-20. doi: 10.1016/j.jmr.2016.07.012. Epub 2016 Jul 27.

PMID:
27522542
31.

Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.

Endocr Relat Cancer. 2016 Oct;23(10):T57-67. doi: 10.1530/ERC-16-0269. Epub 2016 Aug 10. Review.

PMID:
27511924
32.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F.

Br J Cancer. 2016 Jul 26;115(3):281-9. doi: 10.1038/bjc.2016.212. Epub 2016 Jul 12.

33.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.

Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.

PMID:
27353036
34.

Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.

Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, André T, Chibaudel B, Faivre S.

Acta Oncol. 2016 Sep - Oct;55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670. Epub 2016 Jun 22.

PMID:
27333436
35.

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD.

J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.

36.

Electron Paramagnetic Resonance of a Single NV Nanodiamond Attached to an Individual Biomolecule.

Teeling-Smith RM, Jung YW, Scozzaro N, Cardellino J, Rampersaud I, North JA, Šimon M, Bhallamudi VP, Rampersaud A, Johnston-Halperin E, Poirier MG, Hammel PC.

Biophys J. 2016 May 10;110(9):2044-52. doi: 10.1016/j.bpj.2016.03.022.

37.

OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?

Faille D, Ajzenberg N, de Chaisemartin L, Granger V, Chollet-Martin S, de Raucourt E, Hammel P, Lévy P, Ruszniewski P, Rebours V.

Thromb Res. 2016 Apr;140 Suppl 1:S170-1. doi: 10.1016/S0049-3848(16)30123-2. Epub 2016 Apr 8.

PMID:
27161678
38.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group.

JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324.

PMID:
27139057
39.

Nanofiber-based paramagnetic probes for rapid, real-time biomedical oximetry.

Bhallamudi VP, Xue R, Purser CM, Presley KF, Banasavadi-Siddegowda YK, Hwang J, Kaur B, Hammel PC, Poirier MG, Lannutti JJ, Pandian RP.

Biomed Microdevices. 2016 Apr;18(2):38. doi: 10.1007/s10544-016-0063-1.

PMID:
27106026
40.

Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.

Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E.

Nat Rev Clin Oncol. 2016 Sep;13(9):537-49. doi: 10.1038/nrclinonc.2016.37. Epub 2016 Mar 31. Review.

PMID:
27030075
41.

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.

Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P, Buscail L.

Clin Transl Gastroenterol. 2016 Mar 24;7:e157. doi: 10.1038/ctg.2016.18.

42.

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, Maire F, Hammel P, Ruszniewski P, Fenaux P.

Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1. No abstract available.

PMID:
26932783
43.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.

Cancer Med. 2016 Apr;5(4):676-83. doi: 10.1002/cam4.635. Epub 2016 Jan 24.

44.

Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients.

Cesaretti M, Abdel-Rehim M, Barbier L, Dokmak S, Hammel P, Sauvanet A.

J Visc Surg. 2016 Jun;153(3):173-81. doi: 10.1016/j.jviscsurg.2015.11.014. Epub 2016 Jan 13.

PMID:
26775202
45.

Ferromagnetic Resonance Spin Pumping and Electrical Spin Injection in Silicon-Based Metal-Oxide-Semiconductor Heterostructures.

Pu Y, Odenthal PM, Adur R, Beardsley J, Swartz AG, Pelekhov DV, Flatté ME, Kawakami RK, Pelz J, Hammel PC, Johnston-Halperin E.

Phys Rev Lett. 2015 Dec 11;115(24):246602. doi: 10.1103/PhysRevLett.115.246602. Epub 2015 Dec 10.

PMID:
26705647
47.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group.

BMC Cancer. 2015 Oct 6;15:653. doi: 10.1186/s12885-015-1656-4.

48.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.

Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, Hammel P, Lecomte T, Dréanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepère C, Bonnetain F, Taieb J.

Br J Cancer. 2015 Sep 29;113(7):989-95. doi: 10.1038/bjc.2015.328. Epub 2015 Sep 15.

49.

Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.

Bachet JB, Gay F, Maréchal R, Galais MP, Adenis A, MsC DS, Cros J, Demetter P, Svrcek M, Bardier-Dupas A, Emile JF, Hammel P, Ebenezer C, Berlier W, Godfrin Y, André T.

Pancreas. 2015 Oct;44(7):1141-7. doi: 10.1097/MPA.0000000000000394.

PMID:
26355551
50.

Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.

Cros J, Moati E, Raffenne J, Hentic O, Svrcek M, de Mestier L, Sbidian E, Guedj N, Bedossa P, Paradis V, Sauvanet A, Panis Y, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2016;103(5):495-9. doi: 10.1159/000440724. Epub 2015 Sep 4.

PMID:
26335532

Supplemental Content

Loading ...
Support Center